Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. unloaded 4,035 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $13.60, for a total transaction of $54,876.00. Following the transaction, the president now directly owns 130,947 shares of the company’s stock, valued at approximately $1,780,879. The sale was disclosed in a document filed with the SEC, which is available at this link.

NXTM has been the subject of a number of recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. Analysts at Wells Fargo & Co. downgraded shares of NxStage Medical from a “market perform” rating to an “underperform” rating in a research note on Tuesday, March 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. NxStage Medical presently has a consensus rating of “Hold” and a consensus target price of $16.83.

Shares of NxStage Medical (NASDAQ:NXTM) traded down 1.17% during mid-day trading on Monday, hitting $13.57. The stock had a trading volume of 191,725 shares. NxStage Medical has a one year low of $8.77 and a one year high of $15.00. The stock has a 50-day moving average of $12.50 and a 200-day moving average of $12.08. The company’s market cap is $833.4 million.

NxStage Medical (NASDAQ:NXTM) last released its earnings data on Thursday, May 8th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.40 EPS for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.